Last reviewed · How we verify

NCT05503498: PKMF

Pharmacokinetic Model of Fibrinogen Plasma Levels After Fibrinogen Administration

Completed Last updated 16 August 2022
What this trial tests

trial testing DATA RECORDING in Fibrinogen; Deficiency, Acquired in 200 participants. Completed in 1 August 2022.

Timeline
1 January 2021
Primary endpoint
1 January 2022
1 August 2022

Quick facts

Lead sponsorHospital Clinic of Barcelona
StatusCompleted
Study typeOBSERVATIONAL
Enrollment200
Start date1 January 2021
Primary completion1 January 2022
Estimated completion1 August 2022
Sites2 locations across Spain

Drugs / interventions tested

Conditions studied

Sponsor

Hospital Clinic of Barcelona

Who can join

Eligibility, any sex, with Fibrinogen; Deficiency, Acquired or PHARMACOKINETICS. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

characterize the fibrinogen PK in patients with acquired -chronic (cirrhotic patients) or acute- hypofibrinogenemia (severe trauma or critical haermorrhage), showing endogenous production.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Fibrinogen; Deficiency, Acquired

Currently open trials in the same condition.

Other Hospital Clinic of Barcelona trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05503498.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing